Search clinical trials for: Forest Laboratories

Total 6431 results

Southern California Institute for Research and...
Forest Laboratories

Completed

Vilazodone for the Treatment of Posttraumatic Stress Disorder

Depression | PTSD

United States
Massachusetts General Hospital
Forest Laboratories

Completed

Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease (NIRVANA)

Microvascular Angina

United States
Brigham and Women's Hospital
Forest Laboratories; Lahey Clinic

Terminated

The Impact of Nebivolol Versus Metoprolol on Quality of Life

Hypertension | Transplant; Failure, Kidney

United States
Mercy Research
Forest Laboratories

Completed

Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function

Hypertension

United States
Forest Laboratories
Gedeon Richter Ltd.

Completed

Safety and Efficacy of Cariprazine for Mania

Bipolar Disorder | Mania

United States, India
Forest Laboratories
Gedeon Richter Ltd.

Completed

Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania

Bipolar Disorder

United States
Spencer Dorn, MD, MPH
Forest Laboratories

Terminated

Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome

United States
Forest Laboratories
Gedeon Richter Ltd.

Completed

Safety and Efficacy of Cariprazine for Bipolar I Disorder

Mania | Bipolar I Disorder

United States, Croatia, Romania, Russian Federation, Serbia, Ukraine
Emory University
Forest Laboratories

Completed

The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

High Blood Pressure

United States
Stanford University
Forest Laboratories; Palo Alto Veterans Institute for Research

Completed

The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients

Alzheimer Disease

United States
Forest Laboratories

Completed

Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance

Systemic Inflammatory Response Syndrome (SIRS) | Augmented Renal Clearance (ARC)

United States, Australia
NYU Langone Health
Forest Laboratories

Completed

A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction (AcampMet)

Methamphetamine Dependence, Treatment Seeking

United States
Forest Laboratories

Completed

PR-018: An Open-Label, Safety Extension of Study PR-011

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Terminated

Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg

Diarrhea-predominant Irritable Bowel Syndrome

France, Germany
Forest Laboratories

Completed

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

Cystic Fibrosis | Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea

Chronic Pancreatitis | Exocrine Pancreatic Insufficiency | Pancreatectomy

Canada, United States, Poland, Slovakia
Forest Laboratories

Completed

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

Cystic Fibrosis | Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy

Helicobacter Infections

United Kingdom
Forest Laboratories

Completed

Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

Bacterial Infection

United States
Forest Laboratories

Completed

Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age

Infection

United States
Forest Laboratories

Completed

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia (CAP)

Bacterial Pneumonia

United States, Russian Federation, Bulgaria, Germany, Poland, Romania, Ukraine, Argentina, Austria, Brazil, Estonia, France, Georgia, Hungary, India, Lithuania, Malaysia, Serbia, Slovakia, South Africa, Spain, Switzerland, Thailand
Forest Laboratories

Completed

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections (cSSSI)

Bacterial Infections

Argentina, Chile, Mexico, Russian Federation, United States, Poland, Germany, Brazil, Peru, Romania, Ukraine
Forest Laboratories

Completed

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia (CAP)

Bacterial Pneumonia

United States, Argentina, Austria, Bulgaria, Chile, Germany, Hungary, India, Latvia, Mexico, Peru, Poland, Romania, Russian Federation, Ukraine
Forest Laboratories

Completed

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

Bacterial Infections

United States, Chile, Latvia, Poland, Russian Federation, Argentina, Mexico, Austria, Brazil, Germany, Ukraine, United Kingdom
Forest Laboratories

Completed

Bioavailability Study of Anti Nausea Medication With and Without Food (EUR-1025)

Nausea

Canada
Forest Laboratories

Completed

Pharmacokinetic Study of Ondansetron Administered as IR (Zofran) and MR (EUR1025)

Nausea

Canada
Forest Laboratories

Completed

A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021

Eosinophilic Esophagitis

United States
Forest Laboratories

Completed

Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia

Gastroparesis

Australia
Forest Laboratories

Completed

Effects of Itopride on Gastric Motor and Sensory Functions in Healthy Volunteers

Healthy

United States
Forest Laboratories

Completed

Efficacy and Safety of Itopride vs Placebo in Heartburn

Heartburn

United States
Forest Laboratories

Completed

Bioavailability Study of Anti Nausea Medication With and Without Food (EUR-1025) (ODO-P8-689)

Nausea
Forest Laboratories

Terminated

Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure

Portal Hypertension

Spain
Forest Laboratories

Withdrawn

Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori

Helicobacter Pylori Infection

United States, Canada
Forest Laboratories

Completed

Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia

Dyspepsia
Forest Laboratories

Completed

Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal

Dyspepsia

Canada
Forest Laboratories

Completed

Long-Term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia

Dyspepsia
Forest Laboratories

Completed

Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal

Dyspepsia

Canada
Forest Laboratories

Completed

Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient

Congestive Heart Failure

United States
Forest Laboratories

Completed

Effect of Azimilide Dihydrochloride on Renal Function

Healthy

United States
Forest Laboratories

Terminated

A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.

Coronary Artery Disease

United States
Forest Laboratories

Terminated

A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography

Ischemic Heart Disease | Heart Disease

United States
Forest Laboratories

Completed

Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)

Arrhythmias

United States, Canada, Poland, Germany, Spain, Belgium, France
Forest Laboratories

Terminated

A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging

Cardiovascular Disease | Ischemic Heart Disease

United States
University of Missouri-Columbia
Forest Laboratories

Terminated

Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury

Traumatic Brain Injury

United States
Brigham and Women's Hospital
Forest Laboratories

Withdrawn

Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran

Back Pain

United States
Forest Laboratories
National Institute on Drug Abuse (NIDA)

Completed

Acamprosate Initiated During Alcohol Detoxification

Alcohol Use Disorder

United States
Forest Laboratories

Completed

A Study to Determine the Effect of Nitroglycerin Ointment 0.4% (Cellegesic) on the Pain Associated With Chronic Anal Fissures

Pain | Fissure in Ano

Search clinical trials for: Forest Laboratories

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations